The online version of this article (doi:10.1186/1475-2840-11-150) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
JG contributed to the in vivo experiments, participated in the pathological evaluation, interpretation, and acquisition of data, performed statistical analysis, drafted portions of the manuscript, and critically revised the manuscript before final approval. DL participated in the overall design, analysis and interpretation of the data, as well as the writing and presentation of this work. SB participated in the animal model experiments, the data collection and interpretation, performed statistical analysis, drafted portions of the manuscript, and critically revised the manuscript before final approval. TX contributed to the establishment of the animal model as well as the data collection and interpretation. ZZ participated in the model design and the overall conduct of the study. YZ contributed to the study design and data interpretation. All authors read and approved the final manuscript.
Neointimal formation plays an important role in the pathogenesis of coronary restenosis after percutaneous coronary intervention (PCI), especially in patients with diabetes mellitus. Recently, some studies have shown that 5-ethynyl-2'-deoxyuridine (EdU) incorporation can serve as a novel alternative to the 5-bromo-2'-deoxyuridine (BrdU) antibody detection method for detection of DNA synthesis in regenerating avian cochlea, chick embryo and the adult nervous system. However, few studies have been performed to assess the suitability of EdU for detecting DNA synthesis in vascular neointima.
The carotid artery balloon injury model was established in Goto-Kakizaki (GK) and Wistar rats. A Cell-LightTM EdU Kit was used to detect EdU-labeled cell nuclei of common carotid arteries at day 7 after catheter balloon injury. Different methods of injecting EdU were tested. The protein levels of proliferating cell nuclear antigen (PCNA) and p-Akt (Ser473), as well as the mRNA levels of PCNA were evaluated by Western blotting and quantitative real-time PCR (qRT-PCR), respectively. Immunohistochemical staining was also employed to visualize PCNA-positive cells.
At day 7 after catheter balloon injury, far more EdU-positive and PCNA-positive cells were observed in GK rats. When comparing groups that received different EdU doses, it was found that the percentage of EdU-positive cells at a dose of 100 mg/kg body weight was than at doses of 25 mg/kg and 50 mg/kg. The number of positive cells was significantly higher in the repeated injection group compared to the single injection group. Further, after balloon injury DNA synthesis in GK rats was more notable than in Wistar rats. Neointimal formation in GK rats was more obvious than in Wistar rats. The protein levels of PCNA and p-Akt (Ser473) and the mRNA levels of PCNA were increased in injured rats as compared to uninjured rats, and were significantly higher in GK rats than in Wistar rats.
By intraperitoneal injections of EdU at a dose of 100 mg/kg three times, EdU incorporation can detect carotid arterial DNA synthesis caused by neointimal formation in GK rats and Wistar rats at day 7 after balloon injury by the EdU click reaction quickly and effectively. Moreover, more obvious DNA synthesis in the vascular neointima could be observed in GK rats than in Wistar rats.
Authors’ original file for figure 112933_2012_574_MOESM1_ESM.tiff
Authors’ original file for figure 212933_2012_574_MOESM2_ESM.tiff
Authors’ original file for figure 312933_2012_574_MOESM3_ESM.tiff
Authors’ original file for figure 412933_2012_574_MOESM4_ESM.tiff
Authors’ original file for figure 512933_2012_574_MOESM5_ESM.tiff
Authors’ original file for figure 612933_2012_574_MOESM6_ESM.tiff
Park DW, Flaherty JD, Davidson CJ, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ: Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in asian patients. Am J Cardiol. 2009, 103 (5): 646-652. 10.1016/j.amjcard.2008.11.012. CrossRefPubMed
Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004, 109 (19): 2273-2278. 10.1161/01.CIR.0000129767.45513.71. CrossRefPubMed
Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW, TAXUS-IV Investigators: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005, 45 (8): 1172-1179. 10.1016/j.jacc.2004.10.075. CrossRefPubMed
Sheehy A, Hsu S, Bouchard A, Lema P, Savard C, Guy LG, Tai J, Polyakov I: Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries. Cardiovasc Diabetol. 2012, 11: 75-10.1186/1475-2840-11-75. PubMedCentralCrossRefPubMed
Westerweel PE, van Velthoven CT, Nguyen TQ, den Ouden K, de Kleijn DP, Goumans MJ, Goldschmeding R, Verhaar MC: Modulation of TGF-β/BMP-6 expression and increased levels of circulating smooth muscle progenitor cells in a type I diabetes mouse model. Cardiovasc Diabetol. 2010, 9: 5-10.1186/1475-2840-9-5. CrossRef
Buck SB, Bradford J, Gee KR, Agnew BJ, Clarke ST, Salic A: Detection of S-phase cell cycle progression using 5-ethynyl-2′-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2′-deoxyuridine antibodies. Biotechniques. 2008, 44 (7): 927-929. 10.2144/000112812. CrossRefPubMed
Diermeier-Daucher S, Brockhoff G: Dynamic proliferation assessment in flow cytometry. Curr Protoc Cell Biol. 2010, Chapter 8 (Unit 8.6): 1-23.
Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, Lincoff AM, Wang K: Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vasc Biol. 2002, 22 (10): 1598-1603. 10.1161/01.ATV.0000032676.20514.8F. CrossRefPubMed
Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS: Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther. 2006, 317 (1): 37-43. CrossRefPubMed
El-Omar MM, Yang ZK, Phillips AO, Shah AM: Cardiac dysfunction in the Goto-Kakizaki rat. A model of type II diabetes mellitus. Basic Res Cardiol. 2004, 99 (2): 133-141.
Lee CD, Folsom AR, Pankow JS, Brancati FL, Atherosclerosis Risk in Communities (ARIC) Study Investigators: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004, 109 (7): 855-860. 10.1161/01.CIR.0000116389.61864.DE. CrossRefPubMed
Hammound T, Tanguay JF, Bourassa MG: Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol. 2000, 36 (2): 355-365. 10.1016/S0735-1097(00)00732-4. CrossRef
Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR: Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of REStenosis with tranilast and its outcomes (PRESTO) trial. Circulation. 2004, 109 (4): 476-480. 10.1161/01.CIR.0000109693.64957.20. CrossRefPubMed
Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB: Increased restenosis in diabetes mellitus after interventions is due to exaggerated intimal hyperplasia: A serial intravascular ultrasound study. Circulation. 1997, 95 (6): 1366-1369. 10.1161/01.CIR.95.6.1366. CrossRefPubMed
Škalamera D, Ranall MV, Wilson BM, Leo P, Purdon AS, Hyde C, Nourbakhsh E, Grimmond SM, Barry SC, Gabrielli B, Gonda TJ: A high-throughput platform for lentiviral overexpression screening of the human ORFeome. PLoS One. 2011, 6 (5): e20057-10.1371/journal.pone.0020057. (2011). PubMedCentralCrossRefPubMed
Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol. 2001, 21 (7): 1152-1158. 10.1161/hq0701.092104. CrossRefPubMed
Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J, Park KW, Cho HJ, Kang HJ, Park YB, Kim HS: New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol. 2009, 29 (4): 472-479. 10.1161/ATVBAHA.108.176230. CrossRefPubMed
- Detecting DNA synthesis of neointimal formation after catheter balloon injury in GK and in Wistar rats: using 5-ethynyl-2'-deoxyuridine
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II